Acute Myeloid Leukemia – Epidemiology – Emerging Markets

Clarivate Epidemiology’s coverage of acute myeloid leukemia (AML) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of AML for each country, as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and Europe and 10 years for the other countries covered in this report. In addition to forecasting incident and prevalent patient populations, we estimate the number of drug-treatment opportunities in specific lines of therapy in the developed world.

Clarivate Epidemiology’s AML forecast will answer the following questions:

  • Of all people diagnosed with AML, how many in each country in the developed world are drug-treated?
  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of AML over the forecast period?

All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

In total, Clarivate Epidemiology forecasts 17 AML patient populations, including the following:

  • Diagnosed incident cases.
  • Diagnosed incident cases by FLT3 mutation status.
  • Diagnosed incident cases by cytogenetic risk status.
  • Diagnosed first-line AML younger patients (aged < 60) drug-treatable population.
  • Diagnosed first-line AML younger patients (aged < 60) drug-treated population.
  • Diagnosed second-line AML younger patients (aged < 60) drug-treatable population.
  • Diagnosed second-line AML younger patients (aged < 60) drug-treated population.
  • Diagnosed first-line AML older patients (aged ≥ 60) drug-treatable population.
  • Diagnosed first-line AML older patients (aged ≥ 60) drug-treated population.
  • Diagnosed second-line AML older patients (aged ≥ 60) drug-treatable population.
  • Diagnosed second-line AML older patients (aged ≥ 60) drug-treated population.
  • Diagnosed third-line AML drug-treatable population.
  • Diagnosed third-line AML drug-treated population.

Note: Coverage may vary by country.